SAFC Commercial, the custom manufacturing services business unit of Sigma-Aldrich Corp., has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing. The facility is in final validation and expected to go online in 3Q15.
 
The St. Louis expansion, designed to meet SafeBridge category 4 compound handling to safely accommodate usage of highly-active compounds, creates commercial-scale manufacturing capacity for ADCs and other targeted therapies. The expanded capabilities in St. Louis further the company’s commercial capacity for highly-active manufacturing and storage at its Madison, WI facility.
 
“The ADC market is a growing market, and is expected to expand over the next few years. This strategic expansion is the latest in a series of enhancements in our ADC offering designed to support this important therapeutic area and to help our customers to seamlessly scale ADC production from preclinical to commercial phases,” said Gilles Cottier, president of SAFC. “Our offer can bring customers’ molecules to the clinic faster, with the ease of working with one supplier from start to finish. With the added support of our recently launched ADC Express service, we believe SAFC presents the most comprehensive offer in the contract manufacturing market.”